

Catherine Sautes-fridman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8011926/publications.pdf>

Version: 2024-02-01

181
papers

29,900
citations

7561

77
h-index

5677

162
g-index

192
all docs

192
docs citations

192
times ranked

33660
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
2	C1q+ macrophages: passengers or drivers of cancer progression. <i>Trends in Cancer</i> , 2022, 8, 517-526.	3.8	51
3	Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 870862.	2.2	2
4	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. <i>Immunity</i> , 2022, 55, 527-541.e5.	6.6	215
5	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	5.1	66
6	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
7	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
8	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
9	Les structures lympho des tertiaires g n rent et propagent des plasmocytes produisant des anticorps antitumoraux dans le cancer du rein. <i>Medecine/Sciences</i> , 2022, 38, 536-538.	0.0	0
10	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021, 2227, 191-203.	0.4	5
11	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643065.	1.3	26
12	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11507-11507.	0.8	15
13	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. <i>Cancer Immunology Research</i> , 2021, 9, 909-925.	1.6	40
14	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021, 9, 891-908.	1.6	43
15	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.	3.2	39
16	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
17	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
18	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51

#	ARTICLE	IF	CITATIONS
19	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020, 12, 86.	3.6	63
20	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020, 48, 101410.	2.7	81
21	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44
22	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
23	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. <i>Annals of Oncology</i> , 2020, 31, S1157.	0.6	26
24	7000 Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). <i>Annals of Oncology</i> , 2020, 31, S553.	0.6	7
25	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
26	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 393-394.	12.5	9
27	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
28	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
29	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
30	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. <i>Methods in Enzymology</i> , 2020, 632, 15-25.	0.4	3
31	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020, 26, 4381-4389.	3.2	44
32	NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). <i>Annals of Oncology</i> , 2019, 30, v360-v361.	0.6	4
33	NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma. <i>Annals of Oncology</i> , 2019, 30, v400-v401.	0.6	0
34	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 698-715.	12.8	217
35	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
36	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019, 7, 1091-1105.	1.6	153
38	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
39	Revisiting immune escape in colorectal cancer in the era of immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 815-818.	2.9	30
40	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
41	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	1.8	219
42	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
43	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
44	Association of IL-36 β with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	2.0	59
45	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	1.6	81
46	EFISà€¦I Ruggero Ceppellini Advanced Immunology School Course: Tumour immunology 2017: From tissue microenvironment to immunotherapy. Naples 16à€“18 October 2017. <i>European Journal of Immunology</i> , 2018, 48, 559-561.	1.6	1
47	Site-specific N-glycosylation analysis of soluble Fc γ 3 receptor IIIb in human serum. <i>Scientific Reports</i> , 2018, 8, 2719.	1.6	21
48	The Human Tumor Microenvironment. , 2018, , 5-21.		2
49	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018, 51, 97-102.	2.4	29
50	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 981-988.	2.0	89
51	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
52	Intratumoral classical complement pathway promotes tumor growth in renal cancer. <i>Molecular Immunology</i> , 2018, 102, 205.	1.0	0
53	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018, 8, 390.	1.3	46
54	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	3.2	252

#	ARTICLE	IF	CITATIONS
55	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
56	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016, 7, 407.	2.2	238
57	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016, 271, 260-275.	2.8	277
58	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	3.8	1,980
59	50 th Anniversary of the French Society for Immunology (SFI). <i>European Journal of Immunology</i> , 2016, 46, 1545-1547.	1.6	8
60	Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	21
61	Cancer immune contexture and immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 7-13.	2.4	132
62	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433
63	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
64	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016, 76, 1746-1756.	0.4	164
65	Trial Watch: Oncolytic viruses and cancer therapy. <i>OncImmunology</i> , 2016, 5, e1117740.	2.1	88
66	TLS in Tumors: What Lies Within. <i>Trends in Immunology</i> , 2016, 37, 1-2.	2.9	24
67	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
68	Abstract A085: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary clear cell renal cell cancer. , 2016, , .		0
69	Abstract LB-273: Identity card of tumor-infiltrating regulatory T cells in the context of tertiary lymphoid structures in lung cancer patients. , 2016, , .		0
70	Immuno-molecular characterization of colorectal cancer tumors and its clinical implications. <i>Translational Cancer Research</i> , 2016, 5, S368-S370.	0.4	1
71	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		0
72	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncImmunology</i> , 2015, 4, e1049804.	2.1	51

#	ARTICLE	IF	CITATIONS
73	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
74	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	3.2	355
75	Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. <i>Journal of Neuro-Oncology</i> , 2015, 121, 9-18.	1.4	5
76	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	1.4	51
77	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
78	Tumor Immunology, toward a Success Story?. <i>Frontiers in Immunology</i> , 2015, 6, 65.	2.2	2
79	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. <i>Cell Metabolism</i> , 2015, 22, 113-124.	7.2	130
80	Profiling of the Three Circulating Monocyte Subpopulations in Human Obesity. <i>Journal of Immunology</i> , 2015, 194, 3917-3923.	0.4	92
81	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. <i>Clinical Cancer Research</i> , 2015, 21, 1329-1339.	3.2	250
82	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
83	The Non-“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 377-390.	2.5	204
84	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
85	Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. <i>Oncolmmunology</i> , 2014, 3, e28976.	2.1	26
86	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
87	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048.	2.1	69
88	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2014, 3, e957994.	2.1	223
89	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63
90	Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. <i>Cancer Research</i> , 2014, 74, 705-715.	0.4	466

#	ARTICLE	IF	CITATIONS
91	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014, 27, 8-15.	2.4	137
92	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 5008-5018.	0.4	83
93	EFIS: Driving women's representation in immunology in Europe. <i>European Journal of Immunology</i> , 2014, 44, 615-616.	1.6	5
94	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134
95	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014, 35, 571-580.	2.9	418
96	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
97	Shaping of an effective immune microenvironment to and by cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 991-997.	2.0	30
98	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. <i>Chest</i> , 2014, 146, 633-643.	0.4	80
99	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
100	Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 18.	3.5	13
101	Characteristics of tertiary lymphoid structures in primary cancers. <i>Oncolimmunology</i> , 2013, 2, e26836.	2.1	103
102	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. <i>Clinical Cancer Research</i> , 2013, 19, 4079-4091.	3.2	301
103	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e22789.	2.1	92
104	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e26621.	2.1	101
105	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e25595.	2.1	83
106	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e25238.	2.1	132
107	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e24612.	2.1	175
108	Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas. , 2013, 54, 3657.		33

#	ARTICLE	IF	CITATIONS
109	Cytokine Profile in Human Eyes: Contribution of a New Cytokine Combination for Differential Diagnosis between Intraocular Lymphoma or Uveitis. PLoS ONE, 2013, 8, e52385.	1.1	55
110	Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells. Frontiers in Immunology, 2013, 4, 19.	2.2	56
111	Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 189, 3528-3537.	0.4	96
112	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology, 2012, 1, 894-907.	2.1	194
113	Tumor microenvironment in NSCLC suppresses NK cells function. OncoImmunology, 2012, 1, 244-246.	2.1	34
114	The European Academy of Tumor Immunology: Bridging fields, continents and generations. OncoImmunology, 2012, 1, 127-128.	2.1	0
115	Trial watch. OncoImmunology, 2012, 1, 179-188.	2.1	104
116	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	2.1	110
117	Trial Watch. OncoImmunology, 2012, 1, 699-739.	2.1	184
118	FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. British Journal of Cancer, 2012, 106, 1989-1996.	2.9	33
119	Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies. Advances in Hematology, 2012, 2012, 1-13.	0.6	60
120	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in Immunology, 2012, 3, 98.	2.2	14
121	Trial Watch. OncoImmunology, 2012, 1, 306-315.	2.1	70
122	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	2.9	122
123	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191.	0.6	128
124	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	2.1	152
125	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	2.1	103
126	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	2.1	203

#	ARTICLE	IF	CITATIONS
127	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
128	CD14 ^{dim} CD16 ⁺ and CD14 ⁺ CD16 ⁺ Monocytes in Obesity and During Weight Loss. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2322-2330.	1.1	210
129	Characterization of Chemokines and Adhesion Molecules Associated with T cell Presence in Tertiary Lymphoid Structures in Human Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6391-6399.	0.4	245
130	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011, 36, 9-15.	3.0	67
131	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. <i>Cancer Research</i> , 2011, 71, 5601-5605.	0.4	341
132	The immune microenvironments of lung and intraocular tumors. <i>Bulletin Du Cancer</i> , 2011, 98, E58-E61.	0.6	2
133	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
134	Th17 Cells Are Involved in the Local Control of Tumor Progression in Primary Intraocular Lymphoma. <i>PLoS ONE</i> , 2011, 6, e24622.	1.1	21
135	Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. <i>Clinical and Experimental Immunology</i> , 2011, 165, 329-337.	1.1	17
136	Alternative complement pathway assessment in patients with atypical HUS. <i>Journal of Immunological Methods</i> , 2011, 365, 8-26.	0.6	140
137	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 13-25.	2.7	95
138	EFISâ€œ supported events: Courses, Schools, Symposia and Meetings with a European flavour. <i>European Journal of Immunology</i> , 2011, 41, 2467-2469.	1.6	8
139	The 2011 Nobel Prize in Physiology or Medicine: Honor, sadness and lessons. <i>European Journal of Immunology</i> , 2011, 41, 3393-3393.	1.6	2
140	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. <i>Cancer Research</i> , 2011, 71, 5412-5422.	0.4	404
141	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <i>Oncogene</i> , 2010, 29, 1093-1102.	2.6	942
142	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2010, 77, 339-349.	2.6	163
143	Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity. <i>Dermatology Research and Practice</i> , 2010, 2010, 1-11.	0.3	15
144	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193

#	ARTICLE	IF	CITATIONS
145	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1285-1297.	3.9	191
146	The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2009, 46, 447-450.	1.5	142
147	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. <i>Blood</i> , 2009, 114, 2837-2845.	0.6	140
148	Selective expression of inhibitory Fc γ 3 receptor by metastatic melanoma impairs tumor susceptibility to IgG α -dependent cellular response. <i>International Journal of Cancer</i> , 2008, 123, 2832-2839.	2.3	31
149	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008, 124, 562-574.	2.0	25
150	Animal Models of Intraocular Lymphomas. <i>Ophthalmic Research</i> , 2008, 40, 208-211.	1.0	7
151	Super C3-convertases, formed by gain-of-function factor B or C3 mutant proteins are associated with atypical haemolytic uraemic syndrome with a poor outcome. <i>Molecular Immunology</i> , 2008, 45, 4098-4099.	1.0	0
152	Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2008, 30, 238-245.	3.0	28
153	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fc γ 3RIIB. <i>Journal of Immunology</i> , 2008, 181, 5350-5359.	0.4	13
154	Impaired Th1/Tc1 Cytokine Production of Tumor-Infiltrating Lymphocytes in a Model of Primary Intraocular B-Cell Lymphoma. , 2007, 48, 3223.		31
155	Hereditary complement C7 deficiency in nine families: Subtotal C7 deficiency revisited. <i>European Journal of Immunology</i> , 2007, 37, 1377-1385.	1.6	30
156	TRAF4 overexpression is a common characteristic of human carcinomas. <i>Oncogene</i> , 2007, 26, 142-147.	2.6	72
157	A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006, 107, 190-196.	0.6	335
158	Fc gamma receptors and cancer. <i>Seminars in Immunopathology</i> , 2006, 28, 321-328.	4.0	15
159	Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAII α -NR and NCORE α -Fc γ 3RIIB1 interactions, respectively. <i>Journal of General Virology</i> , 2005, 86, 1771-1784.	1.3	65
160	Fc γ 3RIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004, 18, 2038-2040.	3.3	11
161	Fc γ 3RIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004, 124, 55-62.	1.2	25
162	Fc γ 3 receptors. <i>Immunology Letters</i> , 2004, 92, 199-205.	1.1	82

#	ARTICLE	IF	CITATIONS
163	Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.. Blood, 2004, 104, 2264-2264.	0.6	1
164	N-glycosylation profile of recombinant human soluble Fc γ receptor III. Glycobiology, 2002, 12, 507-515.	1.3	22
165	Interleukin-17 inhibits tumor cell growth by means of a T-cell γ dependent mechanism. Blood, 2002, 99, 2114-2121.	0.6	309
166	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood, 2002, 100, 3646-3655.	0.6	78
167	Modulation of tumor growth by inhibitory Fc γ 3 receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	29
168	Modulation of tumor growth by inhibitory Fc γ 3 receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	12
169	Mannose Receptor Ligand-Positive Cells Express the Metalloprotease Decysin in the B Cell Follicle. Journal of Immunology, 2001, 167, 5052-5060.	0.4	31
170	Differential Modulation of Stimulatory and Inhibitory Fc γ 3 Receptors on Human Monocytes by Th1 and Th2 Cytokines. Journal of Immunology, 2001, 166, 531-537.	0.4	215
171	Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1. Journal of Immunology, 2001, 166, 3377-3383.	0.4	32
172	Association of Fc γ 3RII with Low-Density Detergent-Resistant Membranes Is Important for Cross-Linking-Dependent Initiation of the Tyrosine Phosphorylation Pathway and Superoxide Generation. Journal of Immunology, 2001, 167, 5814-5823.	0.4	61
173	The Structure of a Human Type III Fc γ 3 Receptor in Complex with Fc. Journal of Biological Chemistry, 2001, 276, 16469-16477.	1.6	325
174	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. Immunology Letters, 2000, 75, 1-8.	1.1	10
175	Structural basis of the interaction between IgG and fcl γ 3 receptors. Journal of Molecular Biology, 2000, 295, 213-224.	2.0	76
176	Crystal Structure of the Extracellular Domain of a Human Fc γ 3RIII. Immunity, 2000, 13, 387-395.	6.6	98
177	Inhibition of Human Immunodeficiency Virus Transmission to CD4+T Cells after Gene Transfer of Constitutively Expressed Interferon γ 2 to Dendritic Cells. Human Gene Therapy, 2000, 11, 1695-1703.	1.4	5
178	Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins. Journal of Experimental Medicine, 1999, 189, 1217-1228.	4.2	11
179	Regulation of production of soluble Fc γ 3 receptors type III in normal and pathological conditions. Immunology Letters, 1999, 68, 125-134.	1.1	41
180	Control of tumor development by intratumoral cytokines. Immunology Letters, 1999, 68, 135-139.	1.1	27

#	ARTICLE	IF	CITATIONS
181	Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. <i>Cancer Research</i> , 1999, 59, 3698-704.	0.4	235